24 February 2009
Sir William Stewart, Chairman of the Health Protection Agency announced today the appointment of four new non-executive Board members who will take up their posts on 1 April. They are:
Michael Carroll, who has 35 years' experience in the pharmaceutical and biotech industries, working for Glaxo, Novartis, BMS, British Biotech and Scotia in a variety of technical and senior management executive roles both in the UK and internationally. He has extensive practical expertise in the operational management of complex research and development and manufacturing environments and in assisting organisations to deliver their strategic objectives through the execution of effective cultural change programs. Most recently he was Site Director for Novartis UK which focuses on product research, development and manufacturing.
Mr Carroll has served on national committees of the Association of the British Pharmaceutical Industry and the BioIndustry Association where he was active in promoting the UK manufacturing base and industry best practice. He is a founder QP Assessor, a practising QP and a former vice president of the International Society for Pharmaceutical Engineering.
Helen Froud has specialised in Human Resources for more than 15 years. Currently running her own HR and management consultancy carrying out specific HR projects for local authorities, she has previously held executive posts in the financial services and local authority sectors.
A Chartered Member of the Institute of Personnel and Development, and an experienced management trainer and lecturer in Human Resources, Ms Froud is grant-funded by the Commission for Equalities and Human Rights to work on HR projects with small local businesses. She is a Board Member of One Parent Families Scotland and is a regular contributor to professional journals on specialist HR topics, as well as to consumer publications on HR issues for the general public.
Martin Hindle has extensive Board and executive level experience in the UK and international markets in pharmaceuticals and telecommunications. His Board experience covers both private and public sectors. Particular areas of focus include financial management, strategic planning, commercial development, drug development, change and operational management.
As a non executive director of the National Biological Standards Board (NBSB), he chairs the Audit Committee of the National Institute of Biological Standards and Control which is due to become part of the Health Protection Agency in April. Mr. Hindle already serves on the Agency's Finance Committee and will take over the chairmanship of this at the beginning of April.
Mr Hindle is Chairman of the University Hospitals of Leicester NHS Trust.
Deborah Oakley worked in the Financial Services Industry for 20 years until 2006 as an investment manager. She worked for the same company, from its entrepreneurial start up to its eventual sale to a large US corporation, by which time she had become a Board Director. Whilst with the company, Mrs Oakley personally managed assets of £100 million and her team managed assets of £500 million.
Mrs Oakley has been a member of the board of Camden Primary Care Trust for the last two years. She is currently Chair of their Audit Committee and a member of the Finance Committee. She is also a governor of the Royal Free Hospital which hopes to attain Foundation Trust status in the near future.
Sir William Stewart said: "I am delighted to announce these appointments which will significantly strengthen the work of the Board. Michael Carroll's experience in the pharmaceutical and biotech industries will bring an important dimension to the Agency's expanded brief in these areas. Helen Froud's extensive experience in the field of human resources will also be invaluable both to the Board and the wider Agency. Martin Hindle has already served on the National Biological Standards Board and I have no doubt will continue to add value to the Agency's Board. Deborah Oakley's financial and management expertise will bring further rigour to the Board's scrutiny of the Agency's work. I very much welcome these appointments and look forward to all of them contributing fully across the wide spectrum of the Agency's activities."
Notes to Editors
Last reviewed: 24 February 2009